Pharmacovigilance in Nepal: Present Glance and Areas to Improve.

  • Roshan Giri Pharmaceutical Science Programme, School of Health And Allied Sciences, Faculty of Health Science, Pokhara University
  • Aman Kumar Sah Pharmaceutical Science Programme, School of Health And Allied Sciences, Faculty of Health Science, Pokhara University
  • Uday Bir Shahi Pharmaceutical Science Programme, School of Health And Allied Sciences, Faculty of Health Science, Pokhara University
Keywords: Pharmacovigilance, adverse event reporting, quality medicine use, Nepal

Abstract

As the global issues ponder upon the drug safety and Consumer pharmacovigilance, pharmacovigilance in Nepal started from year 2004, however is still at infancy stage. In this commentary we aimed to portray the past and present state of the PV in Nepal along with some of the international and resource limited countries situation along with the areas we can work upon for the effective adverse event reporting, assessment, monitoring and management which leads to the drug safety and quality medicine use in some context in the resource limited countries like Nepal.

Downloads

Download data is not yet available.

References

Abiri, O. T., & Johnson, W. C. N. (2019). Pharmacovigilance systems in resource-limited settings: An evaluative case study of Sierra Leone. Journal of Pharmaceutical Policy and Practice, 12(1), 1–8.

Act, D. (2000). Short title, extent, and commencement: (1). 8(September 1989), 1–15.

Alshakka, M., Palaian, S., & Emirates, U. A. (2010). Ahmed A M, Izham Im, Subish P. Importance Of Consumer Pharmacovigilance System In Developing Countries: A Case Of Malaysia. Journal of Clinical and Diagnostic Research [serial onli... January.

Dal Pan, G. J. (2014). Ongoing challenges in pharmacovigilance. Drug Safety, 37(1), 1–8.

European Medicines Agency. (2017). Annex I GVP. Guideline on Good Pharmacovigilance Practices (GVP), October, 1–33. Retrieved from http://www.jfda.jo/Download/JPC/TheGoodPharmacovigilancePracticev2.pdf

Fornasier, G., Francescon, S., Leone, R., & Baldo, P. (2018). An historical overview over Pharmacovigilance. International Journal of Clinical Pharmacy, 40(4), 744–747.

Fyfe, T. (2007). Turning Research Into Practice (TRIP). Journal of the Medical Library Association, 95(2), 215–216.

Garashi, H. Y., Steinke, D. T., & Schafheutle, E. I. (2022). A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators. Therapeutic Innovation and Regulatory Science, 56(5), 717–743.

Hazell, L., & Shakir, S. A. W. (2006). Under-reporting of adverse drug reactions: A systematic review. Drug Safety, 29(5), 385–396.

ims-health-market-research-and-reports-repository @ www.iqvia.com. (n.d.). https://www.iqvia.com/insights/the-iqvia-institute/available-iqvia-data/ims-health-market-research-and-reports-repository

index @ dohs.gov.np. (n.d.). http://dohs.gov.np/

Jha, N., Palaian, S., Shankar, P. R., Santosh, K. C., & Kshetry, P. B. (2021). Situation analysis of the pharmacovigilance system in Nepal using the indicator-based pharmacovigilance assessment tool (IPAT). Journal of Pharmaceutical Health Services Research, 12(4), 485–491.

Jha, N., Rathore, D. S., Shankar, P. R., Gyawali, S., Hassali, M. A., Alshakka, M., & Alshammri, T. M. (2015). Strengthening adverse drug reaction reporting in Nepal. Asian Journal of Medical Sciences, 6(4), 9–13.

Jha, N., Shankar, P. R., Bajracharya, O., Gurung, S. B., & Singh, K. K. (2012). Adverse drug reaction reporting in a pharmacovigilance centre of Nepal. Australasian Medical Journal, 5(5), 268–271.

Jose, J., Al Rubaie, M. H., Ramimmy, H. Al, & Varughese, S. S. (2021). Pharmacovigilance basic concepts and an overview of the system in oman. Sultan Qaboos University Medical Journal, 21(2), e161–e163.

Jose, J., & Rafeek, N. R. (2019). Pharmacovigilance in India in Comparison With the USA and European Union: Challenges and Perspectives. Therapeutic Innovation and Regulatory Science, 53(6), 781–786.

Kc, S., Tragulpiankit, P., Edwards, I. R., & Gorsanan, S. (2013). Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal. International Journal of Risk and Safety in Medicine, 25(1), 1–16.

Olsson S. (1998). The role of the WHO Programme for International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Safety, 19(1), 1–10.

Olsson, S., Pal, S. N., & Dodoo, A. (2015). Pharmacovigilance in resource-limited countries. Expert Review of Clinical Pharmacology, 8(4), 449–460.

Palaian, S. (2018). Pharmacovigilance Practices and Activities: Issues, Challenges, and Future Direction. In Social and Administrative Aspects of Pharmacy in Low-and Middle-Income Countries: Present Challenges and Future Solutions. Elsevier.

Palaian, S., Ibrahim, M. I., & Mishra, P. (2011). Health professionals’ knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharmacy Practice (Internet), 9(4), 228–235.

Palaian, S., Mohamed Ibrahim, M. I., Mishra, P., Alam, K., Shankar, P. R., & Thapa, B. B. (2010). Pharmacovigilance activities in Nepal. Drug Safety, 33(10), 889–890.

pharmacovigilance @ www.dda.gov.np. (n.d.). https://www.dda.gov.np/content/pharmacovigilance

Pitts, P. J., Louet, H. Le, Moride, Y., & Conti, R. M. (2016). 21St Century Pharmacovigilance: Efforts, Roles, and Responsibilities. The Lancet Oncology, 17(11), e486–e492.

Robert, B., & Brown, E. B. (2004). No 主観的健康感を中心とした在宅高齢者における 健康関連指標に関する共分散構造分析Title. 1, 1–14.

Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013). Data mining of the public version of the FDA adverse event reporting system. International Journal of Medical Sciences, 10(7), 796–803.

Shankar, P. R., Mishra, P., Subish, P., & Upadhyay, D. K. (2007). The drug information center at the Manipal teaching hospital - Going beyond drug information. Drug Information Journal, 41(6), 761–768.

Shrestha, S., Sharma, S., Bhasima, R., Kunwor, P., Adhikari, B., & Sapkota, B. (2020). Impact of an educational intervention on pharmacovigilance knowledge and attitudes among health professionals in a Nepal cancer hospital. BMC Medical Education, 20(1), 1–10.

Strengthening Pharmaceutical Systems (SPS) Program. (2009). Indicator-Based Pharmacovigilance Assessment Tool : Manual for Conducting Assessments in Developing Countries. Strengthening Pharmaceutical Systems (SPS) Program, December, 1–116.

Van Grootheest, K., De Graaf, L., & De Jong-van Den Berg, L. T. W. (2003). Consumer adverse drug reaction reporting: A new step in pharmacovigilance? Drug Safety, 26(4), 211–217.

Worakunphanich, W., Youngkong, S., Suwankesawong, W., Anderson, C., & Thavorncharoensap, M. (2022). Comparison of Patient Adverse Drug Reaction Reporting Systems in Nine Selected Countries. International Journal of Environmental Research and Public Health, 19(8). https://doi.org/10.3390/ijerph19084447

World Health Organization. (2002). The importance of pharmacovigilance. World Health Organization, 48. retrieved from https://www.who.int/publications/i/item/10665-42493

Published
2023-12-01
How to Cite
1.
Giri R, Sah AK, Shahi UB. Pharmacovigilance in Nepal: Present Glance and Areas to Improve. jpadr [Internet]. 2023Dec.1 [cited 2024Feb.21];4(4):1-. Available from: https://jpadr.com/index.php/jpadr/article/view/153